

## **A two-step strategy to reopen America**

Presented by: James M. Todaro, MD (Columbia MD), Joey Krug, Moshe E. Praver, MD (Columbia MD) and Vladimir Zelenko, MD

**April 23, 2020**

### **Abstract**

New antibody tests for SARS-CoV-2 are providing better estimates of the mortality rate of COVID-19. Prior to serology testing, the prevalence of novel-coronavirus infection was calculated to be only 0.26% in the US with a mortality rate of 5.60%. Serology tests, however, now show the infection prevalence to be far higher with a calculated mortality rate of about 0.18%. With age-selective quarantining in combination with widespread testing, telemedicine consultations and early treatment with hydroxychloroquine, azithromycin and zinc, the mortality rate could be reduced to 0.03%. By instituting these measures, the projected number of deaths moving forward could be fewer than the number of deaths in the flu season of 2017-2018.

### **Background**

Without reliable estimates on the mortality rate of COVID-19, many countries including the US took drastic measures to stop the spread of infection and “flatten the curve”. These measures included strict quarantines, travel restrictions and suspension of commercial activity. The result has been havoc on the American economy. A record 26 million Americans sought unemployment benefits this past month.[1] An estimated 7.5 million small businesses may permanently close if the pandemic persists for the next few months.[2] Americans want to visit family and friends, which is prohibited in select states. These were measures taken in a time of uncertainty, which may be coming to an end.

Recently developed rapid serology tests for COVID-19 IgG and IgM antibodies are now available that enable us to more accurately estimate the number of people infected with SARS-CoV-2. Antibody testing allows us to both approximate immunity in populations as well as better estimate the COVID-19 mortality rate.

It has long been suspected that the true infection rate of SARS-CoV-2 is far higher than the prevalence determined by positive tests as reported by Johns Hopkins, The COVID Project and Worldometer.[3][4][5] This is not surprising given delayed availability of testing and new evidence from autopsies that show the first positive COVID-19 cases in the US were in mid-January and not late-February as previously reported.[6] It is now known that the first identified death was a result of community transmission, making it entirely possible that undetected cases were present in the United States as early as December 2019—long before widespread testing was deployed in mid-March.

There are two notable studies released this month on SARS-CoV-2 antibody prevalence in Santa Clara and LA County. The first published on April 11 is a Stanford study of antibody testing in 3,330 subjects in Santa Clara that reports a prevalence of SARS-CoV-2 infection between 2.49% and 4.16% in the local population.[7] A second study by the University of Southern California (USC) published results on April 20 with similar findings in Southern California, estimating antibody prevalence between 2.8% and 5.6% in LA County.[8]


The methodology of these studies—particularly the accuracy of the antibody test—has been challenged despite both studies statistically adjusting prevalence to account for false positives. The infection prevalence results are further validated though upon comparison with Global Epidemic and Mobility Model (GLEAM), an individual-based, stochastic, and spatial epidemic model that inputs real-world data to perform in-silico simulations of the spatial spread of infectious diseases. GLEAM currently estimates a cumulative infection prevalence of 3.4% [2.1% - 5.9%].[9]

Empowered with a more reliable infection rate, as well as population size and known deaths due to COVID-19, we can better approximate the mortality rate of COVID-19.

### COVID-19 mortality rate

The current mortality rate for all ages based on positive COVID-19 testing (not antibody testing) is 5.60%,<sup>[5]</sup> with age distributed mortality rates shown below.

Figure 1. COVID-19 mortality rate by age



Source: Centers for Disease Control and Prevention  
(<https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e2.htm>)

The Stanford study estimates between 48,000 and 81,000 infections in Santa Clara based on antibody testing on April 3-4, 2020 (compared to the 956 documented positive cases at the time). With 50 reported deaths from COVID-19 in Santa Clara and accounting for likely unconfirmed COVID-19 deaths, experts project an upper limit of 100 deaths at the time of study.[7] Based on a 100-death count, the mortality rate of COVID-19 is 0.12% to 0.2%.

The USC study appears to include a more randomized selection of nearly 1,000 subjects, but reports similar results.[8] They estimate an infection prevalence of 221,000 to 442,000 adults in LA County in early April (compared to the 7,994 confirmed cases at the time). This is a multiple of 28 to 55 times higher than the number of reported cases, and implies a mortality rate of 0.14% to 0.27% based on documented deaths from COVID-19 in LA County.

Averaging the mortality rates from these antibody studies result in a **calculated mortality rate of 0.18%** instead of the widely reported 5%.[10]

## **Two-step strategy to reduce mortality**

### **1. Early treatment with hydroxychloroquine, azithromycin and zinc**

The above mortality rates are without widespread early treatment with hydroxychloroquine (HCQ) and azithromycin (AZ), which may reduce the mortality rate by up to 80% according to treatment studies by Didier Raoult MD/PhD in Marseilles.[11][12][13][14] Widespread testing combined with telemedicine consultations and remote EKG monitoring could allow rapid diagnosis and treatment of COVID-19 with HCQ and AZ within 48-72 hours of symptom onset.[15][16] Nearly all antiviral agents effective against acute infections (e.g. Tamiflu, zanamivir, peramivir, zinc, rimantadine and amantadine) are most effective if administered within the first 48 hours of symptom onset.[17] Similarly, HCQ is likely most effective at preventing progression to invasive ventilation and death if administered in this timeframe.


Of note, there is tremendous controversy surrounding the therapeutic effects of HCQ and AZ in treatment of COVID-19. This report is not meant to be a detailed discussion of the efficacy of this treatment option. In brief, however, nearly all studies evaluating the efficacy of HCQ and AZ in *early treatment* of COVID-19 have found significantly reduced mortality rates and/or decreases in viral shedding durations. Furthermore, in the largest survey of physicians treating COVID-19 by Sermo, HCQ was elected the most effective treatment presently available. Recent negative studies showing minimal or no significant benefit of HCQ have all evaluated *late treatment* with HCQ. The average time to treatment in the majority of these negative studies was over 2 weeks from symptom onset to treatment—far too late for the antiviral effects of HCQ to show benefit.[18][19][20][21]

### **2. Age selective self-quarantining**

If persons over age 65 were encouraged to stay home, the mortality rate could be further reduced by limiting the majority of infections to an age range with a very low mortality rate (see Figure 1 above). This could reduce the mortality rate by another 80% to 90%.[22]

In addition to those over age 65, persons with high risk comorbidities should also consider self-quarantine as studies have shown COPD, diabetes and coronary artery disease result in significantly higher rates of admission to ICU, invasive ventilation or death.[23] Shown in Figure 2 below are the leading comorbidities among COVID-19 deaths in New York as of April 22, 2020.

Figure 2. Leading comorbidities among COVID-19 deaths in New York



Source: New York State Department of Health. Data reported daily by hospitals, nursing homes and other healthcare facilities.

Deploying the above two-step strategy, it may be possible to decrease the mortality rate from 0.18% to 0.03% based on the following assumptions. **(1)** Early treatment with HCQ and AZ reduces mortality by at least half (recall the French study estimates a reduction by 80%) resulting in an adjusted mortality rate of 0.09%. **(2)** By encouraging the majority of the elderly and those with high-risk comorbidities to self-quarantine, the mortality rate could be conservatively reduced by another two-thirds resulting in a final COVID-19 adjusted mortality rate of 0.03%.

### Comparison to the seasonal flu

To compare COVID-19 to the seasonal flu (influenza), the most important number is how many people have lost and will lose their lives in this pandemic.

With little immunity, novel-coronavirus is far more contagious than the seasonal flu. Extrapolating the Stanford and USC reported prevalence of 28 to 85 times more cases than the current 822,976 documented positive cases results in a projected 23-70 million US cases as of April 22, 2020.[5] It is possible that more people have been infected with novel-coronavirus in the past 2 months than infected with the flu in an entire flu season. We must account for this as it will increase the total deaths from COVID-19.

Experts and simulation models project that 60-70% of persons (approximately 200 million persons in the US) will be infected with novel-coronavirus before herd immunity is in effect.[24] If we multiply our adjusted mortality rate of 0.03% and 200 million, **we project 60,000 additional deaths over the next few months** (there are currently 46,122 US deaths as of April 22, 2020) from COVID-19 in the United States with quarantining of the elderly and early treatment with HCQ and AZ in effect.[25]

**How does this compare to the seasonal flu?** There were 45 million flu infections in the 2017-2018 flu season with a mortality rate of almost 0.14%, **resulting in a total of 61,000 US deaths**.[26]

## Conclusion

Empowered with a plan to rapidly test and manage COVID-19 patients with telemedicine and treatment with HCQ and AZ, as well as age-selective quarantining, it may be possible to reopen the United States with a projected death count similar to that of a typical flu season.

This strategy could be deployed immediately in states resistant to quarantining, such as Georgia, that are likely to reopen soon regardless. In less than a month, it will be apparent if the strategy is effective and to be replicated in other states. This appears to be the best plan to get the US back to work and our economy back on track.

## Community Steps

1. Disseminate this publication to the medical community. Get their input including risks to this strategy. It will be important for physicians, nurses and healthcare administrators to scale telemedicine operations and stay protected from COVID-19 when possible.
2. Send this publication to local and state policy makers which may include your state governor. They are the ones primarily responsible for altering your state quarantine.
3. Translate this paper into all languages to determine if this strategy could be used in other countries.

## Sources and Comments

[1] Record U.S. jobless claims wipe out post-Great Recession employment gains. April 23, 2020. Article retrieved on April 23, 2020 from <https://www.reuters.com/article/us-usa-economy/record-us-jobless-claims-wipe-out-post-great-recession-employment-gains-idUSKCN2250CS>

[2] Main Street America. The Impact of COVID-19 on Small Businesses. April 9, 2020. Article retrieved on April 23, 2020 from <https://www.mainstreet.org/blogs/national-main-street-center/2020/04/09/new-report-the-impact-of-covid-19-on-small-busines>

[3] Johns Hopkins University. Webpage accessed on April 22, 2020 from <https://coronavirus.jhu.edu/data/cumulative-cases>

- [4] The COVID Tracking Project. Webpage accessed on April 22, 2020 from <https://covidtracking.com/data/us-daily>
- [5] Worldometer. Webpage accessed on April 22, 2020 from <https://www.worldometers.info/coronavirus/country/us/>
- [6] 2 Californians died of coronavirus weeks before previously known 1st US death. April 22, 2020. Article retrieved on April 22, 2020 from <https://www.cnn.com/2020/04/22/us/california-deaths-earliest-in-us/index.html>
- [7] Bendavid E, et al. COVID-19 Antibody Seroprevalence in Santa Clara County, California. medRxiv 2020.04.14.20062463; doi: <https://doi.org/10.1101/2020.04.14.20062463>. <https://www.medrxiv.org/content/10.1101/2020.04.14.20062463v1.full.pdf>
- [8] Preliminary results of USC-LA County COVID-19 study released. April 20, 2020. Article retrieved on April 22, 2020 from <https://pressroom.usc.edu/preliminary-results-of-usc-la-county-covid-19-study-released/>
- [9] GLEAM Project. Webpage accessed on April 23, 2020 from <https://covid19.gleamproject.org/>
- [10] As U.S. coronavirus fatality rate rises to 5 percent, experts are still trying to understand how deadly this virus is. April 17, 2020. Article retrieved on April 22, 2020 from [https://www.washingtonpost.com/health/as-officials-plan-to-reopen-the-economy-a-key-unknown-remains-how-deadly-is-the-coronavirus/2020/04/17/0bd2f938-7e49-11ea-a3ee-13e1ae0a3571\\_story.html](https://www.washingtonpost.com/health/as-officials-plan-to-reopen-the-economy-a-key-unknown-remains-how-deadly-is-the-coronavirus/2020/04/17/0bd2f938-7e49-11ea-a3ee-13e1ae0a3571_story.html)
- [11] Raoult D, et al. Abstract on hydroxychloroquine and azithromycin in treatment of COVID-19 at IHU Méditerranée Infection. Article retrieved on April 23, 2020 from [https://www.mediterranee-infection.com/wp-content/uploads/2020/04/Abstract\\_Raoult\\_EarlyTrtCovid19\\_09042020\\_vD1v.pdf](https://www.mediterranee-infection.com/wp-content/uploads/2020/04/Abstract_Raoult_EarlyTrtCovid19_09042020_vD1v.pdf)
- [12] Méditerranée Infection. Webpage accessed on April 23, 2020 from <http://mediterranee-infection.com/covid-19/>
- [13] Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [published online ahead of print, 2020 Mar 20]. Int J Antimicrob Agents. 2020;105949. doi:10.1016/j.ijantimicag.2020.105949. [https://www.mediterranee-infection.com/wp-content/uploads/2020/03/Hydroxychloroquine\\_final\\_DOI\\_IJAA.pdf](https://www.mediterranee-infection.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA.pdf)
- [14] Gautret P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020 Apr 11:101663. doi: 10.1016/j.tmaid.2020.101663. Article retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151271/>
- [15] Dr. Vladimir Zelenko reports success treating 1,450 COVID-19 positive or suspected patients early with HCQ, AZ and zinc with the assistance of telemedicine as of April 12, 2020.

- [16] R Esper, et al. Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID followed up by telemedicine. April 15, 2020. Article retrieved on April 22, 2020 from <https://www.dropbox.com/s/5qm58cd4fneeci2/2020.04.15%20journal%20manuscript%20final.pdf?dl=0>
- [17] Centers for Disease Control and Prevention. Influenza Antiviral Medications: Summary for Clinicians. Guidelines retrieved on April 23, 2020 from <https://www.cdc.gov/flu/pdf/professionals/antivirals/antiviral-summary-clinician-updated.pdf>
- [18] James Todaro, MD. A compilation of evidence on hydroxychloroquine and azithromycin in treatment of COVID-19. Article retrieved on April 23, 2020 from <https://docs.google.com/document/d/1O6ClS-Oz2ZAgJuyDbnlCEGjMvQPEyM-aaXARUomR9Ww>
- [19] Tang W, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. medRxiv 2020.04.10.20060558; doi: <https://doi.org/10.1101/2020.04.10.20060558>. Article retrieved on April 22, 2020 from <https://www.medrxiv.org/content/10.1101/2020.04.10.20060558v1.full.pdf>
- [20] Magagnoli J, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv 2020.04.16.20065920; doi: <https://doi.org/10.1101/2020.04.16.20065920>. Article retrieved on April 22, 2020 from <https://www.medrxiv.org/content/10.1101/2020.04.16.20065920v1.full.pdf>
- [21] Mahevas M, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. medRxiv 2020.04.10.20060699; doi: <https://doi.org/10.1101/2020.04.10.20060699>. Article retrieved on April 22, 2020 from <https://www.medrxiv.org/content/10.1101/2020.04.10.20060699v1.full.pdf>
- [22] Centers for Disease Control and Prevention. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020. Article retrieved on April 22, 2020 from <https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e2.htm>
- [23] Guan W, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. European Respiratory Journal 2020; DOI: 10.1183/13993003.00547-2020. Article retrieved on April 22, 2020 from <https://erj.ersjournals.com/content/early/2020/03/17/13993003.00547-2020>
- [24] Willem van Schaik, Professor of Microbiology and Infection, University of Birmingham. Expert comments about herd immunity. March 13, 2020. Article retrieved on April 22, 2020 from <https://www.sciencemediacentre.org/expert-comments-about-herd-immunity/>
- [25] Not accounting for these measures, we project approximately 300,000 additional COVID-19 deaths based on a mortality rate of 0.18%.
- [26] Centers for Disease Control and Prevention. 2017-2018 Estimated Influenza Illnesses, Medical visits, Hospitalizations, and Deaths and Estimated Influenza Illnesses, Medical visits, Hospitalizations, and Deaths Averted by Vaccination in the United States. Webpage accessed on April 22, 2020 from <https://www.cdc.gov/flu/about/burden-averted/2017-2018.htm>

## **Acknowledgements**

Special thanks to Mr. Gregory J. Rigano, Esq. and Chandra Duggirala, MD.

## **Disclaimer**

This page and all references are intended for informational purposes only in order to prompt discussion among medical professionals and policy makers. The authors do not make and expressly disclaim all representations and warranties, express, implied, statutory or otherwise, whatsoever, including, but not limited to: (i) warranties of merchantability, fitness for a particular purpose, suitability, usage, title or noninfringement; (ii) that the contents are free from error; and (iii) that such contents will not infringe third-party rights. The parties shall have no liability for damages of any kind arising out of the use, reference to, or reliance on this page or any of the content contained herein, even if advised of the possibility of such damages. In no event will the authors be liable to any person or entity for any damages, losses, liabilities, costs or expenses of any kind, whether direct or indirect, consequential, compensatory, incidental, actual, exemplary, punitive or special for the use of, reference to, or reliance on this paper or any of the content contained herein, including, without limitation, any loss of business, revenues, profits, data, use, goodwill or other intangible losses.